Psychiatric & Substance Abuse Hospitals in European Union 2026: Industry Statistics & Trends

The Psychiatric & Substance Abuse Hospitals industry in the European Union provides short- and long-term inpatient treatment, diagnostic services, and medical care for patients experiencing mental health disorders and substance addictions. The sector is transitioning toward integrated care pathways, heavily utilizing day-hospital structures and specialized units alongside traditional inpatient admissions. According to the latest official figures from Eurostat, there were approximately 318,800 psychiatric care beds in EU hospitals in 2023 (Eurostat), representing 13.9% of all available hospital beds across the Union.

Industry snapshot

Key public data points

Historical & forecast

Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.

What does the Psychiatric & Substance Abuse Hospitals in European Union industry cover?

This industry encompasses the operation of specialized medical facilities providing inpatient, diagnostic, and therapeutic services for individuals suffering from mental illnesses, behavioural disorders, and substance dependencies. Services are delivered under direct medical supervision and cover acute psychiatric care, long-term stabilization, and clinical detoxification.

• •Inpatient activities are officially catalogued under the NACE Rev. 2 classification scheme, specifically within Group 86.10 (Hospital activities).
• •The scope excludes purely residential, non-hospital social care facilities for substance abuse and mental health, which are designated under NACE Group 87.20.
• •Clinical diagnoses treated within these facilities adhere strictly to Chapter V of the ICD-10 (and emerging ICD-11) framework covering codes F00 to F99.

Who operates in the industry and how is it structured?

The European Union's psychiatric hospital market features a hybrid structure dominated by publicly funded healthcare systems, alongside a significant and growing private for-profit and non-profit sector. Operator density and available infrastructure vary widely across individual member states.

• •In 2023, the total number of specialized psychiatric hospital beds across the EU stood at 318,800.
• •Infrastructure distribution is highly country-specific, with Belgium reporting the highest ratio of 139.9 beds per 100,000 inhabitants in 2023.
• •Conversely, Italy reported the lowest provision of inpatient psychiatric beds at just 7.7 per 100,000 inhabitants in 2023, reflecting a highly outpatient-centralized model.

What drives demand in the industry?

Demand for specialized psychiatric and substance abuse treatment is driven by rising epidemiological rates of mental health conditions, workplace burnout, and substance dependencies across Europe. Increased societal awareness and reduced social stigma have also translated into higher clinical presentation and diagnosis rates.

• •Official mortality tracking indicates that 4.1% of all deaths registered across the EU in 2022 resulted directly from mental and behavioural disorders.
• •Alcohol-related mental and behavioural disorders alone accounted for 0.35% of all EU deaths in 2022.
• •The expansion of corporate employee assistance initiatives and enhanced screening protocols in primary care settings further funnel patients into specialized clinical paths.

Who are the notable companies in the industry?

While public healthcare trusts and non-profit religious or civil foundations command a large share of bed capacity, consolidated private healthcare corporations operate substantial specialized psychiatric networks across major EU nations. These operators expand through targeted acquisitions and the integration of specialized mental health sub-brands.

• •Ramsay Santé operates as one of the primary private psychiatric hospital players in Europe, commanding approximately 20% of the private psychiatric hospitalization market in France across 30 dedicated facilities.
• •Clariane SA delivers specialized psychiatric and mental health services across Europe through its dedicated 'Inicea' brand in France and 'Ita Salud Mental' in Spain.
• •emeis (formerly known as ORPEA SA) maintains an extensive multinational footprint across Europe including dedicated short- and long-term psychiatric care facilities.
• •Asklepios Kliniken GmbH & Co. KGaA and Fresenius SE & Co. KGaA (through its Helios division) operate major acute hospital portfolios in Germany containing substantial psychiatric and outpatient mental health departments.

What are the recent trends and outlook?

The industry is witnessing a structural shift away from prolonged institutionalized confinement toward localized, day-hospital models, alternative ambulatory care modes, and digital integration. These hybrid therapeutic practices aim to improve patient integration and optimize capacity constraints.

• •Facilities are increasingly implementing specialized units targeting specific demographics including adolescents, young adults, and geriatric patients suffering from neurodegenerative comorbidities.
• •The European Commission has allocated EUR 1.23 Billion in comprehensive funding to support cross-border mental health initiatives and improve care accessibility across member states.
• •Digital health application frameworks, such as Germany's DiGA system, are being integrated into hospital discharge and outpatient protocols to provide continuous cognitive behavioral therapy support.

How is the industry regulated?

Psychiatric hospitals operate under stringent national healthcare licensing, quality audits, and strict legal frameworks regarding patient rights and involuntary admissions. Funding and reimbursement structures are largely dictated by national statutory health insurance schemes and regional public health budgets.

• •Facilities are subject to standardized clinical performance evaluations, with corporate operators like Clariane striving for widespread ISO 9001 quality certifications across 99% of its facilities.
• •Patient data processing within clinical, diagnostic, and digital therapeutics platforms must strictly comply with the EU General Data Protection Regulation (GDPR).
• •Operational parameters are guided by the European Commission's strategic framework for public health, which mandates a focus on universal access to affordable, high-quality mental healthcare.

Government, statistical and trade sources used for this Claight analysis.

• Eurostat Mental Health and Related Issues Statistics 2023 ·
• Eurostat Health Statistics at Regional Level 2024 ·
• European Commission Public Health Policy Directives 2024 ·
• Ramsay Santé Corporate Financial and Operational Reports 2025 ·
• Clariane SA Integrated Performance and Specialty Care Disclosures 2025 ·
• emeis SA Operational and Strategic Refoundation Updates 2025